{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T06:42:41Z","timestamp":1785825761382,"version":"3.56.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["2017-11174"],"award-info":[{"award-number":["2017-11174"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["2017-11174"],"award-info":[{"award-number":["2017-11174"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["2017-11174"],"award-info":[{"award-number":["2017-11174"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["2017-11174"],"award-info":[{"award-number":["2017-11174"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["2017-11174"],"award-info":[{"award-number":["2017-11174"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogenesis"],"DOI":"10.1038\/s41389-024-00542-1","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T07:44:46Z","timestamp":1732088686000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Identification of pancreatic cancer-specific protease substrates for protease-dependent targeted delivery"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3228-3442","authenticated-orcid":false,"given":"Etienne J.","family":"Slapak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny A.","family":"Zwijnenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0890-7585","authenticated-orcid":false,"given":"Jan","family":"Koster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6627-3229","authenticated-orcid":false,"given":"Maarten F.","family":"Bijlsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2149-4068","authenticated-orcid":false,"given":"C. Arnold","family":"Spek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"542_CR1","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1016\/j.bbamcr.2017.08.004","volume":"1864","author":"R Kappelhoff","year":"2017","unstructured":"Kappelhoff R, Puente XS, Wilson CH, Seth A, L\u00f3pez-Ot\u00edn C, Overall CM. Overview of transcriptomic analysis of all human proteases, non-proteolytic homologs and inhibitors: organ, tissue and ovarian cancer cell line expression profiling of the human protease degradome by the CLIP-CHIP\u2122 DNA microarray. Biochim Biophys Acta Mol Cell Res. 2017;1864:2210\u20139.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"542_CR2","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1074\/mcp.R800012-MCP200","volume":"7","author":"A Doucet","year":"2008","unstructured":"Doucet A, Butler GS, Rodr\u00edguez D, Prudova A, Overall CM. Metadegradomics: toward in vivo quantitative degradomics of proteolytic post-translational modifications of the cancer proteome. Mol Cell Proteom. 2008;7:1925\u201351.","journal-title":"Mol Cell Proteom"},{"key":"542_CR3","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.aller.2016.10.011","volume":"45","author":"S Patel","year":"2017","unstructured":"Patel S. A critical review on serine protease: key immune manipulator and pathology mediator. Allergol Immunopathol. 2017;45:579\u201391.","journal-title":"Allergol Immunopathol"},{"key":"542_CR4","doi-asserted-by":"publisher","first-page":"10275","DOI":"10.3748\/wjg.v22.i47.10275","volume":"22","author":"H Ceuleers","year":"2016","unstructured":"Ceuleers H, Van Spaendonk H, Hanning N, Heirbaut J, Lambeir AM, Joossens J, et al. Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: the role of proteases. World J Gastroenterol. 2016;22:10275\u201386.","journal-title":"World J Gastroenterol"},{"key":"542_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1042\/bse0380095","volume":"38","author":"PN Walsh","year":"2002","unstructured":"Walsh PN, Ahmad SS. Proteases in blood clotting. Essays Biochem. 2002;38:95\u2013111.","journal-title":"Essays Biochem"},{"key":"542_CR6","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/j.molimm.2010.04.020","volume":"47","author":"KM Heutinck","year":"2010","unstructured":"Heutinck KM, ten Berge IJ, Hack CE, Hamann J, Rowshani AT. Serine proteases of the human immune system in health and disease. Mol Immunol. 2010;47:1943\u201355.","journal-title":"Mol Immunol"},{"key":"542_CR7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.bbadis.2014.04.032","volume":"1852","author":"Y Hua","year":"2015","unstructured":"Hua Y, Nair S. Proteases in cardiometabolic diseases: pathophysiology, molecular mechanisms and clinical applications. Biochim Biophys Acta. 2015;1852:195\u2013208.","journal-title":"Biochim Biophys Acta"},{"key":"542_CR8","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.3390\/biomedicines10102477","volume":"10","author":"L Kumar","year":"2022","unstructured":"Kumar L, Bisen M, Khan A, Kumar P, Patel SKS. Role of matrix metalloproteinases in musculoskeletal diseases. Biomedicines. 2022;10:2477.","journal-title":"Biomedicines"},{"key":"542_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32988-5","volume":"13","author":"AP Amini","year":"2022","unstructured":"Amini AP, Kirkpatrick JD, Wang CS, Jaeger AM, Su S, Naranjo S, et al. Multiscale profiling of protease activity in cancer. Nat Commun. 2022;13:5745.","journal-title":"Nat Commun"},{"key":"542_CR10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3390\/biology9040080","volume":"9","author":"EJ Slapak","year":"2020","unstructured":"Slapak EJ, Duitman J, Tekin C, Bijlsma MF, Spek CA. Matrix metalloproteases in pancreatic ductal adenocarcinoma: key drivers of disease progression? Biology. 2020;9:80.","journal-title":"Biology"},{"key":"542_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.5897\/BMBR11.027","volume":"7","author":"S Rakashanda","year":"2012","unstructured":"Rakashanda S, Rana F, Rafiq S, Masood A, Amin S. Role of proteases in cancer: a review. Biotechnol Mol Biol Rev. 2012;7:90\u2013101.","journal-title":"Biotechnol Mol Biol Rev"},{"key":"542_CR12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.biopha.2016.12.021","volume":"86","author":"A Eatemadi","year":"2017","unstructured":"Eatemadi A, Aiyelabegan HT, Negahdari B, Mazlomi MA, Daraee H, Daraee N, et al. Role of protease and protease inhibitors in cancer pathogenesis and treatment. Biomed Pharmacother. 2017;86:221\u201331.","journal-title":"Biomed Pharmacother"},{"key":"542_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11130-022-00949-4","volume":"77","author":"MS Cid-Gallegos","year":"2022","unstructured":"Cid-Gallegos MS, Corzo-R\u00edos LJ, Jim\u00e9nez-Mart\u00ednez C, S\u00e1nchez-Chino XM. Protease inhibitors from plants as therapeutic agents\u2014a review. Plant Foods Hum Nutr. 2022;77:20\u201329.","journal-title":"Plant Foods Hum Nutr"},{"key":"542_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/DDDT.S285852","volume":"15","author":"M Rudzi\u0144ska","year":"2021","unstructured":"Rudzi\u0144ska M, Daglioglu C, Savvateeva LV, Kaci FN, Antoine R, Zamyatnin AA Jr. Current status and perspectives of protease inhibitors and their combination with nanosized drug delivery systems for targeted cancer therapy. Drug Des Dev Ther. 2021;15:9\u201320.","journal-title":"Drug Des Dev Ther"},{"key":"542_CR15","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703.","journal-title":"N Engl J Med"},{"key":"542_CR16","doi-asserted-by":"publisher","first-page":"170986","DOI":"10.1098\/rsos.170986","volume":"5","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Xu J. Mesoporous silica nanoparticle-based intelligent drug delivery system for bienzyme-responsive tumour targeting and controlled release. R Soc Open Sci. 2018;5:170986.","journal-title":"R Soc Open Sci"},{"key":"542_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202300964","volume":"35","author":"Q Tang","year":"2023","unstructured":"Tang Q, Sun S, Wang P, Sun L, Wang Y, Zhang L, et al. Genetically engineering cell membrane-coated BTO nanoparticles for MMP2-activated piezocatalysis-immunotherapy. Adv Mater. 2023;35:e2300964.","journal-title":"Adv Mater"},{"key":"542_CR18","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.2147\/IJN.S402249","volume":"18","author":"R Li","year":"2023","unstructured":"Li R, Liu C, Wan C, Liu T, Zhang R, Du J, et al. A targeted and pH-responsive nano-graphene oxide nanoparticle loaded with doxorubicin for synergetic chemo-photothermal therapy of oral squamous cell carcinoma. Int J Nanomed. 2023;18:3309\u201324.","journal-title":"Int J Nanomed"},{"key":"542_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.120990","volume":"275","author":"Y Feng","year":"2021","unstructured":"Feng Y, Xie X, Zhang H, Su Q, Yang G, Wei X, et al. Multistage-responsive nanovehicle to improve tumor penetration for dual-modality imaging-guided photodynamic-immunotherapy. Biomaterials. 2021;275:120990.","journal-title":"Biomaterials"},{"key":"542_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2022.112927","volume":"220","author":"K Li","year":"2022","unstructured":"Li K, Zhou D, Cui H, Mo G, Liu Y, Zheng K, et al. Size-transformable gelatin\/nanochitosan\/doxorubicin nanoparticles with sequentially triggered drug release for anticancer therapy. Colloids Surf B Biointerfaces. 2022;220:112927.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"542_CR21","doi-asserted-by":"publisher","first-page":"7622","DOI":"10.1016\/j.biomaterials.2014.05.050","volume":"35","author":"HX Wang","year":"2014","unstructured":"Wang HX, Yang XZ, Sun CY, Mao CQ, Zhu YH, Wang J. Matrix metalloproteinase 2-responsive micelle for siRNA delivery. Biomaterials. 2014;35:7622\u201334.","journal-title":"Biomaterials"},{"key":"542_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.aca.2023.341203","volume":"1260","author":"Y Shen","year":"2023","unstructured":"Shen Y, Xin Z, Pan X, Zhang Y, Jia H, Fu X, et al. Multifunctional fluorescent mesoporous carbon nanoprobe for MMP-2-activated cancer cell imaging and targeted photothermal therapy. Anal Chim Acta. 2023;1260:341203.","journal-title":"Anal Chim Acta"},{"key":"542_CR23","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.3390\/cancers13133321","volume":"13","author":"EJ Slapak","year":"2021","unstructured":"Slapak EJ, Kong L, El Mandili M, Nieuwland R, Kros A, Bijlsma MF, et al. ADAM9-responsive mesoporous silica nanoparticles for targeted drug delivery in pancreatic cancer. Cancers (Basel). 2021;13:3321.","journal-title":"Cancers (Basel)"},{"key":"542_CR24","doi-asserted-by":"publisher","first-page":"8058","DOI":"10.1039\/C5NR04119H","volume":"8","author":"SH van Rijt","year":"2016","unstructured":"van Rijt SH, B\u00f6l\u00fckbas DA, Argyo C, Wipplinger K, Naureen M, Datz S, et al. Applicability of avidin protein coated mesoporous silica nanoparticles as drug carriers in the lung. Nanoscale. 2016;8:8058\u201369.","journal-title":"Nanoscale"},{"key":"542_CR25","doi-asserted-by":"publisher","first-page":"12752","DOI":"10.1021\/acsomega.2c07949","volume":"8","author":"H Wu","year":"2023","unstructured":"Wu H, Ding X, Chen Y, Cai Y, Yang Z, Jin J. Constructed tumor-targeted and MMP-2 biocleavable antibody conjugated silica nanoparticles for efficient cancer therapy. ACS Omega. 2023;8:12752\u201360.","journal-title":"ACS Omega"},{"key":"542_CR26","doi-asserted-by":"publisher","first-page":"10704","DOI":"10.3390\/ijms241310704","volume":"24","author":"EJ Slapak","year":"2023","unstructured":"Slapak EJ, El Mandili M, Brink MST, Kros A, Bijlsma MF, Spek CA. Preclinical assessment of ADAM9-responsive mesoporous silica nanoparticles for the treatment of pancreatic cancer. Int J Mol Sci. 2023;24:10704.","journal-title":"Int J Mol Sci"},{"key":"542_CR27","doi-asserted-by":"publisher","first-page":"13333","DOI":"10.1021\/acsnano.3c01428","volume":"17","author":"J Kuang","year":"2023","unstructured":"Kuang J, Rao ZY, Zheng DW, Kuang D, Huang QX, Pan T, et al. Nanoparticles hitchhike on monocytes for glioblastoma treatment after low-dose radiotherapy. ACS Nano. 2023;17:13333\u201347.","journal-title":"ACS Nano"},{"key":"542_CR28","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1021\/nn5070343","volume":"9","author":"SH van Rijt","year":"2015","unstructured":"van Rijt SH, B\u00f6l\u00fckbas DA, Argyo C, Datz S, Lindner M, Eickelberg O, et al. Protease-mediated release of chemotherapeutics from mesoporous silica nanoparticles to ex vivo human and mouse lung tumors. ACS Nano. 2015;9:2377\u201389.","journal-title":"ACS Nano"},{"key":"542_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216845","volume":"590","author":"EJ Slapak","year":"2024","unstructured":"Slapak EJ, El Mandili M, Ten Brink MS, Kros A, Bijlsma MF, Spek CA. CAPN2-responsive mesoporous silica nanoparticles: a promising nanocarrier for targeted therapy of pancreatic cancer. Cancer Lett. 2024;590:216845.","journal-title":"Cancer Lett"},{"key":"542_CR30","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1093\/brain\/awg285","volume":"126","author":"A Bar-Or","year":"2003","unstructured":"Bar-Or A, Nuttall RK, Duddy M, Alter A, Kim HJ, Ifergan I, et al. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain. 2003;126:2738\u201349.","journal-title":"Brain"},{"key":"542_CR31","doi-asserted-by":"publisher","first-page":"9739","DOI":"10.3390\/ijms21249739","volume":"21","author":"GA Cabral-Pacheco","year":"2020","unstructured":"Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, Ramirez-Acu\u00f1a JM, Perez-Romero BA, Guerrero-Rodriguez JF, et al. The roles of matrix metalloproteinases and their inhibitors in human diseases. Int J Mol Sci. 2020;21:9739.","journal-title":"Int J Mol Sci"},{"key":"542_CR32","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1158\/1541-7786.MCR-16-0180","volume":"14","author":"B Gr\u00fcnwald","year":"2016","unstructured":"Gr\u00fcnwald B, Vandooren J, Gerg M, Ahomaa K, Hunger A, Berchtold S, et al. Systemic ablation of MMP-9 triggers invasive growth and metastasis of pancreatic cancer via deregulation of IL6 expression in the bone marrow. Mol Cancer Res. 2016;14:1147\u201358.","journal-title":"Mol Cancer Res"},{"key":"542_CR33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.critrevonc.2008.02.008","volume":"68","author":"P Benes","year":"2008","unstructured":"Benes P, Vetvicka V, Fusek M. Cathepsin D-many functions of one aspartic protease. Crit Rev Oncol Hematol. 2008;68:12\u201328.","journal-title":"Crit Rev Oncol Hematol"},{"key":"542_CR34","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.tibs.2018.07.003","volume":"43","author":"M Vizovi\u0161ek","year":"2018","unstructured":"Vizovi\u0161ek M, Vidmar R, Drag M, Fonovi\u0107 M, Salvesen GS, Turk B. Protease specificity: towards in vivo imaging applications and biomarker discovery. Trends Biochem Sci. 2018;43:829\u201344.","journal-title":"Trends Biochem Sci"},{"key":"542_CR35","doi-asserted-by":"publisher","first-page":"e1003007","DOI":"10.1371\/journal.pcbi.1003007","volume":"9","author":"JE Fuchs","year":"2013","unstructured":"Fuchs JE, von Grafenstein S, Huber RG, Margreiter MA, Spitzer GM, Wallnoefer HG, et al. Cleavage entropy as quantitative measure of protease specificity. PLoS Comput Biol. 2013;9:e1003007.","journal-title":"PLoS Comput Biol"},{"key":"542_CR36","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1111\/febs.14001","volume":"284","author":"P Kasperkiewicz","year":"2017","unstructured":"Kasperkiewicz P, Poreba M, Groborz K, Drag M. Emerging challenges in the design of selective substrates, inhibitors and activity-based probes for indistinguishable proteases. FEBS J. 2017;284:1518\u201339.","journal-title":"FEBS J"},{"key":"542_CR37","doi-asserted-by":"publisher","first-page":"7583","DOI":"10.1073\/pnas.0511108103","volume":"103","author":"KT Boulware","year":"2006","unstructured":"Boulware KT, Daugherty PS. Protease specificity determination by using cellular libraries of peptide substrates (CLiPS). Proc Natl Acad Sci USA. 2006;103:7583\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"542_CR38","doi-asserted-by":"publisher","first-page":"358","DOI":"10.2174\/138620710791054259","volume":"13","author":"ML Moss","year":"2010","unstructured":"Moss ML, Rasmussen FH, Nudelman R, Dempsey PJ, Williams J. Fluorescent substrates useful as high-throughput screening tools for ADAM9. Comb Chem High Throughput Screen. 2010;13:358\u201365.","journal-title":"Comb Chem High Throughput Screen"},{"key":"542_CR39","doi-asserted-by":"publisher","first-page":"6033","DOI":"10.1002\/adfm.201601703","volume":"26","author":"S Tang","year":"2016","unstructured":"Tang S, Meng QS, Sun HP, Su JH, Yin Q, Zhang ZW, et al. Tumor-microenvironment-adaptive nanoparticles codeliver paclitaxel and siRNA to inhibit growth and lung metastasis of breast cancer. Adv Funct Mater. 2016;26:6033\u201346.","journal-title":"Adv Funct Mater"},{"key":"542_CR40","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.1021\/acsami.5b11619","volume":"8","author":"T Ji","year":"2016","unstructured":"Ji T, Li S, Zhang Y, Lang J, Ding Y, Zhao X, et al. An MMP-2 responsive liposome integrating antifibrosis and chemotherapeutic drugs for enhanced drug perfusion and efficacy in pancreatic cancer. ACS Appl Mater Interfaces. 2016;8:3438\u201345.","journal-title":"ACS Appl Mater Interfaces"},{"key":"542_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-022-01265-4","volume":"20","author":"XY Liu","year":"2022","unstructured":"Liu XY, Zhu MH, Wang XY, Dong X, Liu HJ, Li RY, et al. A nano-innate immune system activator for cancer therapy in a 4T1 tumor-bearing mouse model. J Nanobiotechnol. 2022;20:54.","journal-title":"J Nanobiotechnol"},{"key":"542_CR42","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1021\/nn300524f","volume":"6","author":"L Zhu","year":"2012","unstructured":"Zhu L, Kate P, Torchilin VP. Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano. 2012;6:3491\u20138.","journal-title":"ACS Nano"},{"key":"542_CR43","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1021\/acsnano.6b05541","volume":"11","author":"H Han","year":"2017","unstructured":"Han H, Valdep\u00e9rez D, Jin Q, Yang B, Li Z, Wu Y, et al. Dual enzymatic reaction-assisted gemcitabine delivery systems for programmed pancreatic cancer therapy. ACS Nano. 2017;11:1281\u201391.","journal-title":"ACS Nano"},{"key":"542_CR44","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1021\/acsami.2c18184","volume":"15","author":"Y He","year":"2023","unstructured":"He Y, Tian X, Fan X, Gong X, Tan S, Pan A, et al. Enzyme-triggered size-switchable nanosystem for deep tumor penetration and hydrogen therapy. ACS Appl Mater Interfaces. 2023;15:552\u201365.","journal-title":"ACS Appl Mater Interfaces"},{"key":"542_CR45","doi-asserted-by":"publisher","first-page":"5068","DOI":"10.1021\/ja312004m","volume":"135","author":"J Zhang","year":"2013","unstructured":"Zhang J, Yuan ZF, Wang Y, Chen WH, Luo GF, Cheng SX, et al. Multifunctional envelope-type mesoporous silica nanoparticles for tumor-triggered targeting drug delivery. J Am Chem Soc. 2013;135:5068\u201373.","journal-title":"J Am Chem Soc"},{"key":"542_CR46","first-page":"4062","volume":"63","author":"AM Mansour","year":"2003","unstructured":"Mansour AM, Drevs J, Esser N, Hamada FM, Badary OA, Unger C, et al. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res. 2003;63:4062\u20136.","journal-title":"Cancer Res"},{"key":"542_CR47","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.micromeso.2013.08.050","volume":"182","author":"J-H Xu","year":"2013","unstructured":"Xu J-H, Gao F, Li LL, Ma HL, Fan Y, Liu W, et al. Gelatin\u2013mesoporous silica nanoparticles as matrix metalloproteinases- degradable drug delivery systems in vivo. Microporous Mesoporous Mater. 2013;182:165\u201372.","journal-title":"Microporous Mesoporous Mater"},{"key":"542_CR48","first-page":"1512","volume":"5","author":"R de Sousa Abreu","year":"2009","unstructured":"de Sousa Abreu R, Penalva LO, Marcotte EM, Vogel C. Global signatures of protein and mRNA expression levels. Mol Biosyst. 2009;5:1512\u201326.","journal-title":"Mol Biosyst"},{"key":"542_CR49","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrg3185","volume":"13","author":"C Vogel","year":"2012","unstructured":"Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet. 2012;13:227\u201332.","journal-title":"Nat Rev Genet"},{"key":"542_CR50","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/pmic.201200493","volume":"13","author":"J Klein","year":"2013","unstructured":"Klein J, Eales J, Z\u00fcrbig P, Vlahou A, Mischak H, Stevens R, et al. Proteasix: a tool for automated and large-scale prediction of proteases involved in naturally occurring peptide generation. Proteomics. 2013;13:1077\u201382.","journal-title":"Proteomics"},{"key":"542_CR51","doi-asserted-by":"publisher","first-page":"10761","DOI":"10.3390\/ijms241310761","volume":"24","author":"EV Matveev","year":"2023","unstructured":"Matveev EV, Safronov VV, Ponomarev GV, Kazanov MD. Predicting structural susceptibility of proteins to proteolytic processing. Int J Mol Sci. 2023;24:10761.","journal-title":"Int J Mol Sci"},{"key":"542_CR52","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1016\/S0021-9258(18)53472-4","volume":"268","author":"D Br\u00f6mme","year":"1993","unstructured":"Br\u00f6mme D, Bonneau PR, Lachance P, Wiederanders B, Kirschke H, Peters C, et al. Functional expression of human cathepsin S in Saccharomyces cerevisiae. Purification and characterization of the recombinant enzyme. J Biol Chem. 1993;268:4832\u201328.","journal-title":"J Biol Chem"},{"key":"542_CR53","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1172\/JCI107641","volume":"53","author":"AI Sapolsky","year":"1974","unstructured":"Sapolsky AI, Howell DS, Woessner JF Jr. Neutral proteases and cathepsin D in human articular cartilage. J Clin Invest. 1974;53:1044\u201353.","journal-title":"J Clin Invest"},{"key":"542_CR54","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00395-004-0499-3","volume":"100","author":"RH Naseem","year":"2005","unstructured":"Naseem RH, Hedegard W, Henry TD, Lessard J, Sutter K, Katz SA. Plasma cathepsin D isoforms and their active metabolites increase after myocardial infarction and contribute to plasma renin activity. Basic Res Cardiol. 2005;100:139\u201346.","journal-title":"Basic Res Cardiol"},{"key":"542_CR55","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/978-1-4615-1871-6_47","volume":"362","author":"T Azuma","year":"1995","unstructured":"Azuma T, Yamada M, Murakita H, Nishikawa Y, Kohli Y, Yamamoto K, et al. Cathepsin E expressed in pancreatic cancer. Adv Exp Med Biol. 1995;362:363\u20136.","journal-title":"Adv Exp Med Biol"},{"key":"542_CR56","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1515\/hsz-2015-0114","volume":"396","author":"RD Wilkinson","year":"2015","unstructured":"Wilkinson RD, Williams R, Scott CJ, Burden RE. Cathepsin S: therapeutic, diagnostic, and prognostic potential. Biol Chem. 2015;396:867\u201382.","journal-title":"Biol Chem"},{"key":"542_CR57","doi-asserted-by":"publisher","first-page":"15430","DOI":"10.1021\/bi00047a006","volume":"34","author":"LB Giebel","year":"1995","unstructured":"Giebel LB, Cass RT, Milligan DL, Young DC, Arze R, Johnson CR. Screening of cyclic peptide phage libraries identifies ligands that bind streptavidin with high affinities. Biochemistry. 1995;34:15430\u20135.","journal-title":"Biochemistry"},{"key":"542_CR58","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/protein\/gzn020","volume":"21","author":"JJ Rice","year":"2008","unstructured":"Rice JJ, Daugherty PS. Directed evolution of a biterminal bacterial display scaffold enhances the display of diverse peptides. Protein Eng Des Sel. 2008;21:435\u201342.","journal-title":"Protein Eng Des Sel"}],"container-title":["Oncogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41389-024-00542-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-024-00542-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-024-00542-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T09:04:06Z","timestamp":1732093446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41389-024-00542-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["542"],"URL":"https:\/\/doi.org\/10.1038\/s41389-024-00542-1","relation":{},"ISSN":["2157-9024"],"issn-type":[{"value":"2157-9024","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,20]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.F.B. has received research funding from Celgene, Lead Pharma, and Frame Therapeutics, and acted as a consultant to Servier, Olympus, and Wholomics. None of these were involved in the design of this study nor the drafting of the paper.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The use of whole blood was evaluated and approved by the Ethics Committee of the Amsterdam University Medical Centers and performed following the instructions from the Declaration of Helsinki. The animal tissues were collected in accordance with the regulations on animal experimentation and approved by the ethics committee of Amsterdam University Medical Centers (Approval number: AVD118002015222).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The blood donor has provided consent for the usage of the collected blood in scientific research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"40"}}